Abbott To Acquire Solvay Pharmaceuticals Business

Abbott has announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay’s pharmaceuticals business for E4.5 billion ($6.6 billion) in cash. The transaction will provide Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets. The acquisition also includes full global rights to the fenofibrate franchise. Currently Abbott has US rights to fenofibrate and pays royalties to Solvay.

The acquisition will also add approximately $500m to Abbott’s annual pharmaceutical R&D investment, providing Abbott with the opportunity to further accelerate near and long-term pharmaceutical growth.

Miles White, chairman and chief executive officer of Abbott, said: “The acquisition of Solvay Pharmaceuticals further diversifies our pharmaceutical portfolio, expands our presence in key high-growth emerging markets, enhances our investment in R&D and accelerates our long-term earnings-per-share growth outlook.

“In anticipation of future market needs, we are ensuring we have the technologies, products, infrastructure and reach to serve patients globally and continue to deliver sustainable industry-leading growth. This acquisition, as well as the others we’ve announced this year all contribute to achieving that long-term goal.”

Christian Jourquin, chief executive officer of Solvay, said: “With this transaction Solvay Pharmaceuticals has found a new strong home, within a respected company with a solid and committed position in the industry,”

Solvay’s pharmaceutical portfolio complements Abbott’s presence and expertise in specialty markets such as cardiovascular disease, neuroscience and gastroenterology. Solvay has treatments for Parkinson’s disease, Meniere’s disease (abnormality of the inner ear), vertigo, and irritable bowel syndrome. Solvay also offers products to treat men’s and women’s hormonal health, and exocrine pancreatic insufficiency (inability to properly digest food), which is associated with several underlying conditions including cystic fibrosis and chronic pancreatitis.

The acquisition also includes Solvay’s vaccines business, which will provide Abbott entry into the expanding global vaccines market. Solvay has a small molecular diagnostics unit that will become part of Abbott’s diagnostics organization upon the transaction close.

“Abbott’s international pharmaceutical business has grown significantly over the past several years, driven by specialty products in developed markets,” said Olivier Bohuon, executive vice president, Pharmaceutical Products Group, Abbott. “In emerging markets where chronic disease is being treated more aggressively, the combined Abbott and Solvay portfolio of branded generics expands the global reach of these medicines. Solvay’s business will also give us a platform to enter the attractive global vaccines market.”